A Phase IIb Study to Investigate VesiGel (Mitomycin) for the Treatment of Low Grade Non-Muscle Invasive Bladder Cancer (LG NMIBC)

Trial Profile

A Phase IIb Study to Investigate VesiGel (Mitomycin) for the Treatment of Low Grade Non-Muscle Invasive Bladder Cancer (LG NMIBC)

Planning
Phase of Trial: Phase II

Latest Information Update: 21 Mar 2018

At a glance

  • Drugs Mitomycin (Primary)
  • Indications Bladder cancer
  • Focus Therapeutic Use
  • Sponsors UroGen Pharma
  • Most Recent Events

    • 21 Mar 2018 New trial record
    • 15 Mar 2018 According to an UroGen Pharma media release, the company intends to submit an Investigational New Drug (IND) application with the FDA for VesiGel for the treatment of LG NMIBC in Q2 2018 and commence this phase 2b trial shortly thereafter.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top